Financial Analysis: Cybin (OTCMKTS:CYBN) and InMed Pharmaceuticals (OTCMKTS:IMLFF)

Cybin (OTCMKTS:CYBN) and InMed Pharmaceuticals (OTCMKTS:IMLFF) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Earnings & Valuation

This table compares Cybin and InMed Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	$680,000.00	312.82	-$35.93 million	($6.66)	-1.60
InMed Pharmaceuticals	N/A	N/A	N/A	($0.05)	-87.68

InMed Pharmaceuticals has lower revenue, but higher earnings than Cybin. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cybin and InMed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-93.17%	-84.68%
InMed Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings for Cybin and InMed Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0	0	1	0	3.00
InMed Pharmaceuticals	0	0	0	0	0.00

Institutional & Insider Ownership

17.9% of Cybin shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cybin beats InMed Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Cybin

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.